Format

Send to

Choose Destination
Hematology Am Soc Hematol Educ Program. 2015;2015:649-51. doi: 10.1182/asheducation-2015.1.649.

Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs).

Author information

1
Department of Leukemia, MD Anderson Cancer Center, Houston, TX; and.
2
Division of Hematology & Medical Oncology, Mayo Clinic in Arizona, Scottsdale, AZ.

Abstract

A 69-year-old man presents with a Dynamic International Prognostic Scoring System (DIPSS) intermediate-risk 2 post polycythemia vera myelofibrosis with significant splenomegaly, 30 pound weight loss, constitutional symptoms, and 2% peripheral blood blasts. He has no other significant past medical history and no other major comorbid conditions. You are asked by the hematology fellow you are supervising whether or not treating this patient with a Janus kinase (JAK) inhibitor will decrease major morbid events.

PMID:
26637784
DOI:
10.1182/asheducation-2015.1.649
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center